Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional

A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

ClinicalTrials.gov ID: NCT05785624

Public ClinicalTrials.gov record NCT05785624. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 1:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Two-Cohort, Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of Vixarelimab Compared With Placebo in Patients With Idiopathic Pulmonary Fibrosis and in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease

Study identification

NCT ID
NCT05785624
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Genentech, Inc.
Industry
Enrollment
286 participants

Conditions and interventions

Interventions

  • Vixarelimab Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 85 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 25, 2023
Primary completion
Jan 11, 2026
Completion
Jan 11, 2026
Last update posted
Feb 8, 2026

2023 – 2026

United States locations

U.S. sites
28
U.S. states
14
U.S. cities
24
Facility City State ZIP Site status
University of Alabama at Birmingham Birmingham Alabama 35233
Banner University Medicine Lung Institute Phoenix Arizona 85006-2506
Southern Arizona VA Health Care System NAVREF PPDS Tucson Arizona 85723-0001
University of California, San Francisco-Fresno Fresno California 93701-2302
University of Southern California Keck School of Medicine Los Angeles California 90033-1036
UCLA Rheumatology Los Angeles California 90095-8344
University of California, San Francisco Medical Center San Francisco California 94143-2204
The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Cente Torrance California 90502
Renstar Medical Research Ocala Florida 34470
Coastal Pulmonary and Critical Care PLC St. Petersburg Florida 33704-2733
Weston Hospital Weston Florida 33331-3609
Piedmont Pulmonary and Sleep Medicine Buckhead Atlanta Georgia 30309-1740
Emory Clinic Atlanta Georgia 30322
GenHarp Clinical Solutions Evergreen Park Illinois 60805-2758
Northwestern Medicine - Northwestern Medicine Glen Glenview Illinois 60026-8039
IU Health Ball Memorial Physicians Pulmonary and Critical Care Medicine Muncie Indiana 47303-3432
University of Kansas Medical Center Kansas City Kansas 66160
University of Michigan Hospital Ann Arbor Michigan 48109
Hannibal Regional Healthcare System HRMG Hannibal Hannibal Missouri 63401-6890
Pulmonix LLC Greensboro North Carolina 27403-4443
Southeastern Research Center Winston-Salem North Carolina 27103-4029
The University of Oklahoma Health Sciences Center Oklahoma City Oklahoma 73104-5417
Baylor Scott and White Health - Advanced Lung Disease Specialists - Dallas Dallas Texas 75246-2073
IntraCare Health Center ? Prestige Dallas Texas 75254
El Paso Pulmonary Association Elligo PPDS El Paso Texas 79902-1124
McGovern Medical School Houston Texas 77030-1501
Baylor College of Medicine Houston Texas 77030
University of Utah - PPDS Salt Lake City Utah 84108-1287

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 86 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05785624, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 8, 2026 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05785624 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →